SUMMARY Background
Hepatorenal syndrome type 1 (HRS1) is a functional, rapidly progressive, potentially reversible form of acute kidney injury occurring in patients with cirrhosis. Characterised by intense renal arterial vasoconstriction, it carries a very poor prognosis. There is a significant unmet need for a widely approved, safe and effective pharmacological treatment.
Aim
To re-evaluate efficacy and safety of pharmacological treatments for HRS1, in the light of recently published randomised controlled trials (RCTs).
Methods

MEDLINE (OvidSP), EMBASE, PubMed and Cochrane registers were searched for
RCTs reporting efficacy and adverse events related to pharmacological treatment of HRS1. Search terms included: 'hepatorenal syndrome', 'terlipressin', 'noradrenaline', 'octreotide', 'midodrine', 'vasopressin', 'dopamine', 'albumin' and synonyms. Comparison of vasoactive drugs vs. placebo/no treatment, and two active drugs were included. Meta-analysis was performed for HRS1 reversal, creatinine improvement, mortality and adverse events.
Results
Twelve RCTs enrolling 700 HRS1 patients were included. Treatment with terlipressin and albumin led to HRS1 reversal more frequently than albumin alone or placebo (RR: 2.54, 95% CI: 1.51-4.26). Noradrenaline was effective in reversing HRS1, but trials were small and nonblinded. Overall, there was mortality benefit with terlipressin (RR: 0.79, 95% CI: 0.63-1.01), but sensitivity analysis including only trials with low risk of selection bias weakened this relationship (RR: 0.87, 95% CI: 0.71-1.06). Notably, there was a significant risk of adverse events with terlipressin therapy (RR: 4.32, 95% CI: 0.75-24.86).
INTRODUCTION
Hepatorenal syndrome (HRS) is a severe form of acute kidney injury (AKI) that typically occurs in patients with decompensated liver cirrhosis, but is also a frequent complication of fulminant hepatic failure and acute alcoholic hepatitis. HRS remains a diagnosis of exclusion 1 and is associated with a dismal prognosis. 2 With an estimated annual incidence in the USA of 9000-14 000 patients, HRS is present in approximately 15% of patients admitted to hospital with ascites and develops in more than 50% of cirrhotics who die. 3 Clinically, there are two distinct types of HRS. Type-1 HRS (HRS1) is characterised by rapidly progressive kidney failure, which is most frequently precipitated by acute bacterial infection and a dysregulated systemic inflammatory response. If left untreated, HRS1 has a 2-week mortality rate of~80%. 4 In contrast, renal impairment in type-2 HRS (HRS2) is slower in onset and progression and typically occurs in patients with refractory ascites. The median survival of HRS2 is around 6 months without liver transplantation. 4 Intense renal arterial vasoconstriction is thought to be the central mechanism underlying the functional renal failure that characterises HRS. 5 In cirrhosis, HRS occurs in response to portal hypertension and splanchnic arterial vasodilatation that results in a reduction in effective circulating volume. The development of a hyperdynamic circulation and activation of homoeostatic neurohormonal mechanisms (such as the reninangiotensin-aldosterone system, vasopressin and the sympathetic nervous system) maintain arterial blood pressure via increased cardiac output and heart rate, heightened systemic vascular tone, and sodium and water retention, but also causes renal vasoconstriction. 6 Pooling of blood in the splanchnic circulation also alters gut permeability and enhances bacterial translocation, with the release of endotoxin and increase in pro-inflammatory cytokines leading to amplification of circulatory dysfunction. 7 As cirrhosis and splanchnic vasodilation progress, cardiac output is no longer able to compensate and systemic hypotension occurs. 6 The combination of hypotension and peripheral vasoconstriction leads to reduced tissue perfusion in extrasplanchnic organs including the kidneys and brain. 8 This 'splanchnic steal phenomenon' leaves patients vulnerable to episodes of non-HRS AKI, HRS and hepatic encephalopathy. HRS develops when renal blood flow falls below the level required to maintain glomerular filtration rate.
The optimum treatment for HRS is liver transplantation, but this is limited by donor availability and patients often die before transplantation can occur. Interestingly, renal artery resistive indices can take up to a year to return to normal following transplant 9 and recovery of renal function is not universal. 10 Indeed, complete recovery of kidney function only occurred in 58% of patients within 4-110 days of liver transplantation, 15% partially recovered, and 25% never recovered. 10 Many previous studies evaluating the efficacy and safety of these agents were small, uncontrolled, nonblinded and poorly designed. In the last decade several randomised controlled trials (RCTs) have been published with varying conclusions. Some of these trials combined patients with HRS1 and HRS2 despite significant differences in the severity, rate of progression, and prognosis of these conditions. More recently, a number of appropriately powered, well-designed RCTs in patients with HRS1 alone have been reported.
In the light of recent advancements in the literature, the aim of this systematic review and meta-analysis was to re-evaluate the efficacy and safety of available pharmacological treatments for HRS1.
METHODS
Study design
This systematic review and meta-analysis was registered in the PROSPERO international prospective register of systematic reviews (CRD42016042921) and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). 12 Search strategy and study selection An electronic search was performed through to June 2016 using MEDLINE (OvidSP), EMBASE, PubMed and both the Cochrane Central Register of Controlled Trials, and the Cochrane Hepatobiliary Group Register. Manual searches of selected speciality journals and conference proceedings (Appendix S1) were performed to identify all pertinent literature. Similarly, reference lists from published clinical trials and previous systematic reviews were examined. Our search was limited to human studies that were published in English. No date limitation was applied.
Search terms included 'hepatorenal syndrome', 'terlipressin', 'noradrenaline', 'octreotide', 'midodrine', 'vasopressin', 'dopamine', 'albumin' and their synonyms. Studies deemed eligible for inclusion were RCTs in adults (≥18 years) with HRS1 as defined by the International Ascites Club in 2007. 13 Comparisons between two pharmacological agents, or one active drug and placebo/ no treatment were included. Moreover, papers were excluded if they did not report one or more of the outcomes of interest, as outlined in Table 1 . One investigator (FJG) performed an initial review of all titles to exclude duplicates and nonrelevant literature. Two investigators (JAF and FJG) then independently judged eligibility of all abstracts. A third investigator (JRM) reviewed a subset (10%) of studies to check the accuracy of selection and data extraction, and to resolve any disagreements that emerged.
Data extraction and study quality assessment Two investigators (JAF and FJG) independently extracted data using a standardised data collection form in Microsoft Excel version 15.20 (Redmond, Washington, USA). Extracted data included patient characteristics, treatment arm, comparator groups, and selected outcomes. In addition, country of origin, single or multi-centre status, randomisation and blinding procedures, funding source, duration of follow-up, number of patient withdrawals, and appropriate powering of the study were noted. Where possible, data were extracted as intention-to-treat analyses.
The quality of included studies was appraised using the Cochrane Collaboration's tool for assessing the risk of bias.
14 Risk of bias was judged as low, high or unclear within seven domains: sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, missing outcome data, selective reporting and other sources of bias.
Study outcomes and statistical analysis
Outcomes of interest included HRS1 reversal (as defined by each individual trial), improved serum creatinine (sCr), and all-cause mortality. In addition, data were recorded on adverse events, focussing specifically on ischaemic adverse events. The relative risk (RR) and 95% confidence intervals (95% CI) were calculated for each outcome. Meta-analysis was performed using a MantelHaenszel random-effects model in view of the expected heterogeneity between trials (varying inclusion criteria, treatment dose, duration and definition of outcomes).
The heterogeneity between studies was quantified using the I 2 statistic with I 2 < 25% representing low heterogeneity, 25-50% moderate and >50% I 2 high inter-trial heterogeneity. Each therapeutic method was analysed separately. A sensitivity analysis of treatment effect was undertaken using only trials judged as having low risk of selection bias on the grounds of sequence generation and allocation concealment. 15 All analyses were performed using REVMAN version 5.3 (Nordic Cochrane Centre, Copenhagen, Denmark).
RESULTS
Study characteristics and risk of bias
The literature search identified a total of 2739 manuscripts. A total of 894 papers were duplicates, and 1629 citations were removed after screening of titles. A further 169 publications were excluded after abstract review, leaving 24 full text articles. Twelve studies were excluded: six as after contacting the primary authors for further information only an abstract was available; two were not RCTs; three did not separate HRS1 and HRS2 patients when reporting their results; and one further study (Hadengue et al., 1998) 16 was later excluded due to insufficient outcome reporting.
A total of 12 papers were included in the final analysis ( Figure 1) . [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] All included studies were RCTs. Treatment comparisons included terlipressin, noradrenaline, octreotide and midodrine, low-dose dopamine, and placebo. All trials used albumin or a similar plasma expander in both treatment and comparator groups. Four studies included both HRS1 and HRS2 patients, but reported results for the HRS1 subgroup independently. 19, [26] [27] [28] Study characteristics are shown in Table 2 .
A total of 700 participants with HRS1 were included in our series. Mean age was 53 years, and participants were 74% male (Silawat et al. 23 did not publish the age or sex of their participants). Overall treatment time varied between 5 and 19 days, with a mean of 14 days. Average albumin dose was 12.5-40 g/day. In two multicentre studies, concomitant albumin use was recommended but not universally applied. 17, 21 Four studies allowed paracentesis for tense ascites when required. 22, 25, 26, 28 Two of these stated that additional albumin therapy was given during paracentesis. 22, 28 Length of follow-up varied between 15 and 180 days. Five studies (45%) had 90-day follow-up (Table 2) . Silawat et al. 23 did not define length of follow-up.
In studies examining the use of terlipressin, the initial terlipressin dose varied from 1 mg/day to 6 mg/day. Six of the 10 studies increased the terlipressin dose on day 3-5 if only a partial response was seen. 17-19, 21, 22, 24 The maximum dose of terlipressin was 8-12 mg/day. Neri et al. 20 routinely reduced terlipressin dose on day 5 from 3 mg/day to 1.5 mg/day. In studies using noradrenaline, the dose was recorded as 0.5-3 mg/h 22, 24 or 0.1-0.7 lg/kg/min.
27, 28
Bias Seventeen per cent studies had high risk of bias for allocation concealment, 83% for blinding of participants and 58% for blinding of outcome assessment. Two trials were double-blinded (18%). 17, 21 One was reported to be single-blinded, however, it did not state if the blinding referred to the patient or investigator. 25 Nine studies (75%) were nonblinded, although one open-label study reported that outcome assessors were blinded. 26 Twentyfive of included studies were judged to have a high risk of bias due to incomplete outcome data and a further 8% for selective reporting. Fifty-eight per cent of trials published a sample size calculation. Boyer et al. amended the recruitment target mid-trial, then continued to recruit until 30 patients had achieved complete HRS1 reversal. 17 The trial by Martin-Llahi et al. was terminated early after interim analysis revealed an unexpectedly low event rate. 19 Similarly, the study by Table 3 .
Results of data analysis by comparison
The definition of HRS1 reversal varied across studies and for two trials the diagnostic criteria was not specified. 23, 25 Only two studies used the existing gold standard definition of 'two sCr measurements of ≤132 lmol/L on two occasions, at least 48 h apart without death, renal replacement therapy or HRS1 recurrence'. 17, 21 For meta-analysis, the definition of HRS1 reversal was taken as a sCr ≤ 132 lmol/L on at least one occasion. Eleven of the 12 included trials reported mortality data for HRS1 patients. Martin-Llahi et al. did not subdivide mortality data by HRS1 and HRS2 and therefore, this study was not included in this analysis. 19 Reporting of adverse events was also variable between studies. Frequently listed complaints included abdominal pain/presumed intestinal ischaemia, myocardial infarction, arrhythmias, electrocardiogram changes and digital ischaemia. The study by Alessandria et al. was unclear with regard to adverse event rates, stating that 'most' patients treated with terlipressin experienced transient abdominal cramps and watery diarrhoea. Consequently, adverse event data from this study was included in the meta-analysis for ischaemic adverse events only. 28 Terlipressin + albumin vs. no intervention/placebo + albumin. Terlipressin plus albumin significantly increased the chance that a patient would achieve HRS1 reversal (RR: 2.54, 95% CI: 1.51-4.26; I 2 52%; Figure 2 ) compared to albumin alone, or with placebo. A similar, but more modest result was obtained when the analysis was restricted to papers with low risk of selection bias (RR: 2.11, 95% CI: 1.28-3.49; I 2 40%; Analysis 1.3 in Data S1).
Three studies provided additional information on patients who showed a partial response to vasoconstrictor therapy (drop by >50% from baseline sCr). [18] [19] [20] Analysis of all patients with improved sCr favoured the use of terlipressin vs. placebo (RR: 1.66, 95% CI: 1.07-2.57, Figure 2 Figure 3 ). Further analysis showed the RR of an ischaemic adverse event whilst using terlipressin to be 3.56 (95% CI: 1.64-7.72) compared to placebo. terlipressin infusion (RR: 1.22, 95% CI: 0.77-1.93, Analysis 2.1 in Data S1). 18 Moreover, terlipressin infusion led to greater sCr improvement (RR: 1.18, 95% CI: 0.87-1.59, Analysis 2.2 in Data S1), reduced the risk of all adverse events (RR: 0.48, 95% CI: 0.22-1.01, Analysis 2.4 Supp Material), and specifically ischaemic adverse events (RR: 0.63, 95% CI: 0.28-1.42) compared with bolus therapy. Despite this, infusion of terlipressin was inferior to bolus therapy with respect to mortality rate (RR: 1.58, 95% CI: 0.86-2.91, Analysis 2.3 in Data S1).
Terlipressin + albumin vs. noradrenaline + albumin. Terlipressin and noradrenaline treatment performed equally with regard to HRS1 reversal (RR: 0.99, 95% CI: 0.67-1.45, Analysis 3.1 in Data S1). However, mortality rate with terlipressin was marginally worse compared with noradrenaline (RR: 1.04, 95% CI: 0.74-1.47, Analysis 3.2 in Data S1). The use of terlipressin significantly increased the risk of all adverse events when compared with noradrenaline (RR: 2.14, 95% CI: 0.81-5.69, Analysis 3.3 in Data S1). However, terlipressin induced fewer ischaemic adverse events than noradrenaline, although numbers were small (RR: 0.63, 95% CI: 0.15-2.59).
Terlipressin + albumin vs. dopamine + standard care. For HRS1 reversal, the evaluation of terlipressin vs. low-dose dopamine favoured terlipressin (RR: 2.00, 95% CI: 1.14-3.52, Analysis 4.1 in Data S1). However, in this comparison terlipressin treatment did not show a significant survival benefit (RR: 0.98, 95% CI: 0.76-1.26, Analysis 4.2 in Data S1), although participant numbers were small. Terlipressin significantly increased the risk of all adverse events (RR: 4.79, 95% CI: 0.46-49.60, Analysis 4.3 in Data S1) and ischaemic adverse events (RR: 2.18, 95% CI 0.51-9.34) when compared with low-dose dopamine.
Noradrenaline + albumin vs. Octreotide, Midodrine + albumin. Noradrenaline performed better than midodrine and octreotide for achieving HRS1 reversal (RR: 1.25, 95% CI: 0.70-2.24, Analysis 5.1 in Data S1), but was found to be inferior in reducing mortality (RR: 1.50, 95% CI: 0.60-3.78, Analysis 5.2 in Data S1). No adverse events were reported for either treatment in this study.
DISCUSSION
HRS1 is a rapidly fatal disease if left untreated. Until recently, a significant proportion of the literature consisted of poorly designed, nonblinded studies with incomplete outcome reporting. In addition, some studies had pooled both HRS1 and HRS2 patients together.
Given the significant disparity in speed of onset and progression, severity and outcomes related to these two conditions, we believe that they should be considered separately. Recently, larger well-designed and appropriately powered RCTs have shed further light on this important area. 17, 18 A prior systematic review Recording of adverse events was unreliable in several studies, with possible reporting bias and the suggestion that low adverse event rates were related to lower doses of terlipressin. Pooled data comparing terlipressin and noradrenaline showed no evidence of superiority of terlipressin over noradrenaline for achieving HRS1 reversal (RR: 0.99, 95% CI: 0.67-1.45. Terlipressin appeared marginally inferior to noradrenaline with regard to mortality (RR: 1.04, 95% CI: 0.74-1.47). Notably, the CI for both of these results crossed 1, so the validity of these data are uncertain. Furthermore, the three trials comparing noradrenaline and terlipressin were small, nonblinded, single centre studies. 22, 24, 28 Meta-analysis suggested fewer ischaemic adverse events with noradrenaline, although patient numbers were small and CI broad. Noradrenaline was superior to octreotide and midodrine with respect to HRS1 reversal, but not survival or adverse event rate. Interestingly, Matto et al. recently compared both the efficacy and cost of terlipressin and noradrenaline therapy. 30 Their study reinforced previous literature concluding that neither vasoconstrictor was superior with respect to HRS1 reversal or 30-day mortality. However, unlike other economic analyses where only the cost of the vasoconstrictor drug was considered, Matto et al. calculated all direct medical costs involved in a hypothetical hospitalisation using each of the studied medications. These calculations included the costs accrued in the intensive care unit, where a patient must be monitored if noradrenaline is infused. This economic evaluation is arguably a more accurate assessment of real-world costs, and suggested that terlipressin is a more cost-effective treatment than noradrenaline. In addition, Salerno et al. recently published a metaanalysis of 19 studies (eight RCTs, eight prospective and three retrospective studies) suggesting a dose-response relationship between albumin therapy and survival in HRS1 patients. 31 As Indeed, some patients labelled as HRS1 were reported to have 'refractory ascites', which is more typically associated with HRS2. This may, in part, explain the variation seen in historical meta-analyses of vasoconstrictor therapies for HRS. The use of stringent criteria for study inclusion and the addition of recent high quality studies, may arguably render the results of our updated metaanalysis more reliable.
A recent meta-analysis by Belcher et al. suggested that improvement in sCr, when taken as a continuous variable, was a valid surrogate marker for mortality. 32 This implies that even partial improvement in sCr may lead to improved short-term survival. Importantly, some patients now survive long enough to undergo liver transplantation. Furthermore, as pre-transplant renal dysfunction is associated with increased morbidity and mortality after liver transplantation, any increase in renal function (whether complete or partial HRS reversal) may improve outcomes. 33 In contrast, survival in HRS1 'nonresponders' is extremely low. 34 In view of the severity of this condition and limitations of currently available drug therapy, the Food and Drug Administration recently granted HRS orphan disease status in an attempt to accelerate the development of more effective treatments. An ideal treatment for HRS1 would theoretically consist of a drug with selective vasodilator activity in the renal circulation but without significant vasodilator effects in other vascular beds, especially the splanchnic circulation. However, nitrates may have potentially deleterious effects on renal function in cirrhosis. 35 Fenoldopam, a selective dopamine-1 receptor agonist with renoprotective properties, has been evaluated in patients with post-operative AKI 36 but randomised placebo-controlled studies in cirrhosis are lacking. Other investigational agents such as the thromboxane receptor antagonist ifetrobam (ClinicalTrials.gov: NCT01436500) and the relaxin family peptide receptor-1 agonist serelaxin (ClinicalTrials.gov: NCT01640964) are in clinical development and may have therapeutic potential for the treatment of portal hypertension and/or renal dysfunction in cirrhosis.
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